Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

134.30 

0.98 0.7%

as of Mar 20 '23

52 Week Range:

132.40 293.80


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 22.86
19.87
20.94
27.40
33.95
39.43
37.38
19.94
16.52
15.47
12.96
growth rate -13.1% 5.4% 30.9% 23.9% 16.1% -5.2% -46.7% -17.2% -6.4% -16.2%
Earnings BIT 3,271.86
3,949.88
4,154.87
6,765.00
8,629.00
9,832.00
10,340.00
10,551.00
9,740.00
9,328.00
9,338.00
growth rate 20.7% 5.2% 62.8% 27.6% 13.9% 5.2% 2.0% -7.7% -4.2% 0.1%
Avg.PE 13.40
15.58
17.24
20.56
14.93
14.83
55.13
52.51
16.31
17.21
17.21
growth rate 16.3% 10.7% 19.3% -27.4% -0.7% 271.8% -4.8% -68.9% 5.5% 0.0%
ROA 7.98
8.42
8.44
7.63
9.87
10.35
2.51
11.47
12.44
11.84
9.50
growth rate 5.5% 0.2% -9.6% 29.4% 4.9% -75.8% 357.0% 8.5% -4.8% -19.8%
ROE 17.14
22.82
24.69
21.55
25.77
26.65
7.18
44.48
70.73
76.13
73.16
growth rate 33.1% 8.2% -12.7% 19.6% 3.4% -73.1% 519.5% 59.0% 7.6% -3.9%
ROIC 9.84
11.24
11.35
10.33
12.69
13.30
3.53
16.87
19.31
19.92
16.86
growth rate 14.2% 1.0% -9.0% 22.9% 4.8% -73.5% 377.9% 14.5% 3.2% -15.4%
Cur. Ratio 4.80
3.81
3.44
4.95
4.44
4.11
5.49
2.79
1.44
1.81
1.59
growth rate -20.6% -9.7% 43.9% -10.3% -7.4% 33.6% -49.2% -48.4% 25.7% -12.2%
Quick Ratio 4.09
3.24
2.78
4.22
3.97
3.68
4.98
2.44
1.01
1.30
1.06
growth rate -20.8% -14.2% 51.8% -5.9% -7.3% 35.3% -51.0% -58.6% 28.7% -18.5%
Leverage 2.57
2.85
2.99
2.68
2.55
2.60
3.17
5.31
6.17
6.69
9.13
growth rate 10.9% 4.9% -10.4% -4.9% 2.0% 21.9% 67.5% 16.2% 8.4% 36.5%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 2,283.21
1,985.19
2,126.31
2,546.00
2,995.00
3,165.00
3,237.00
4,201.00
4,652.00
5,324.00
5,839.00
growth rate -13.1% 7.1% 19.7% 17.6% 5.7% 2.3% 29.8% 10.7% 14.5% 9.7%
Acct.Payable 995.00
965.00
917.00
1,352.00
1,207.00
1,371.00
1,421.00
1,366.00
growth rate -3.0% -5.0% 47.4% -10.7% 13.6% 3.7% -3.9%
Cur.Assets 21,754.32
24,605.18
21,576.14
34,713.00
38,515.00
46,010.00
49,476.00
37,618.00
18,440.00
21,144.00
19,385.00
growth rate 13.1% -12.3% 60.9% 11.0% 19.5% 7.5% -24.0% -51.0% 14.7% -8.3%
Total Assets 38,529.90
42,808.54
52,132.95
69,009.00
71,449.00
77,626.00
79,954.00
66,416.00
59,707.00
62,948.00
61,165.00
growth rate 11.1% 21.8% 32.4% 3.5% 8.7% 3.0% -16.9% -10.1% 5.4% -2.8%
Cash 5,476.23
2,567.82
2,999.86
3,731.00
4,144.00
3,241.00
3,800.00
6,945.00
6,037.00
6,266.00
7,989.00
growth rate -53.1% 16.8% 24.4% 11.1% -21.8% 17.3% 82.8% -13.1% 3.8% 27.5%
Inventory 1,958.39
2,163.37
2,380.18
2,647.00
2,435.00
2,745.00
2,834.00
2,940.00
3,584.00
3,893.00
4,086.00
growth rate 10.5% 10.0% 11.2% -8.0% 12.7% 3.2% 3.7% 21.9% 8.6% 5.0%
Cur.Liabilities 4,536.45
6,457.78
6,265.41
7,008.00
8,664.00
11,204.00
9,020.00
13,488.00
12,835.00
11,653.00
12,184.00
growth rate 42.4% -3.0% 11.9% 23.6% 29.3% -19.5% 49.5% -4.8% -9.2% 4.6%
Liabilities 23,527.43
27,781.64
34,712.46
43,231.00
43,366.00
47,751.00
54,713.00
53,916.00
50,034.00
53,539.00
54,465.00
growth rate 18.1% 25.0% 24.5% 0.3% 10.1% 14.6% -1.5% -7.2% 7.0% 1.7%
LT Debt 16,827.61
18,948.41
23,354.77
30,215.00
29,182.00
30,193.00
34,190.00
29,510.00
26,950.00
32,895.00
33,222.00
growth rate 12.6% 23.3% 29.4% -3.4% 3.5% 13.2% -13.7% -8.7% 22.1% 1.0%
Equity 15,002.46
15,026.90
17,420.49
25,778.00
28,083.00
29,875.00
25,241.00
12,500.00
9,673.00
9,409.00
6,700.00
growth rate 0.2% 15.9% 48.0% 8.9% 6.4% -15.5% -50.5% -22.6% -2.7% -28.8%
Common Shares 912.00
787.00
765.00
770.00
766.00
754.00
735.00
31,246.00
31,531.00
31,802.00
32,096.00
growth rate -13.7% -2.8% 0.7% -0.5% -1.6% -2.5% 4,151.2% 0.9% 0.9% 0.9%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 447.02
543.21
546.36
718.00
594.00
738.00
664.00
738.00
618.00
608.00
880.00
growth rate 21.5% 0.6% 31.4% -17.3% 24.2% -10.0% 11.1% -16.3% -1.6% 44.7%
Cash Dividends 394.20
881.43
1,115.59
1,851.00
2,396.00
2,998.00
3,365.00
3,507.00
3,509.00
3,755.00
4,013.00
growth rate 123.6% 26.6% 65.9% 29.4% 25.1% 12.2% 4.2% 0.1% 7.0% 6.9%
Cash From OA 4,035.82
4,637.37
4,959.82
8,952.00
9,731.00
10,354.00
11,177.00
11,296.00
9,150.00
10,497.00
9,261.00
growth rate 14.9% 7.0% 80.5% 8.7% 6.4% 8.0% 1.1% -19.0% 14.7% -11.8%
FCF per Share 4.15
5.56
4.33
7.58
10.34
9.84
11.82
13.32
13.23
14.08
11.94
growth rate 34.0% -22.1% 75.1% 36.4% -4.8% 20.1% 12.7% -0.7% 6.4% -15.2%
Sale Purchase of Stock 186.00
-1,867.00
-2,965.00
-3,160.00
growth rate -100.0% 0.0% 0.0%
FCF 4,552.00
5,193.00
5,598.00
7,552.00
8,428.00
9,517.00
10,513.00
10,558.00
8,532.00
9,889.00
8,381.00
growth rate 14.1% 7.8% 34.9% 11.6% 12.9% 10.5% 0.4% -19.2% 15.9% -15.3%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 12,284.85
13,611.73
14,724.16
20,063.00
21,662.00
22,991.00
22,849.00
23,747.00
23,362.00
25,424.00
25,979.00
growth rate 10.8% 8.2% 36.3% 8.0% 6.1% -0.6% 3.9% -1.6% 8.8% 2.2%
Op.Income 3,399.58
4,396.91
4,625.54
6,765.00
8,629.00
9,832.00
10,340.00
10,551.00
9,740.00
9,328.00
9,338.00
growth rate 29.3% 5.2% 46.3% 27.6% 13.9% 5.2% 2.0% -7.7% -4.2% 0.1%
IBT 3,271.86
3,949.10
4,150.93
5,585.00
7,978.00
9,163.00
9,597.00
9,545.00
9,138.00
8,133.00
6,701.00
growth rate 20.7% 5.1% 34.6% 42.9% 14.9% 4.7% -0.5% -4.3% -11.0% -17.6%
Net Income 2,903.68
3,425.60
4,005.86
5,158.00
6,939.00
7,722.00
1,979.00
8,394.00
7,842.00
7,264.00
5,893.00
growth rate 18.0% 16.9% 28.8% 34.5% 11.3% -74.4% 324.2% -6.6% -7.4% -18.9%
EPS 4.04
5.52
6.64
6.70
9.06
10.24
2.69
12.62
12.88
12.31
10.28
growth rate 36.6% 20.3% 0.9% 35.2% 13.0% -73.7% 369.1% 2.1% -4.4% -16.5%
Gross Profit 10,371.40
11,089.63
12,086.17
15,745.00
17,487.00
18,829.00
18,780.00
19,646.00
19,006.00
19,265.00
19,525.00
growth rate 6.9% 9.0% 30.3% 11.1% 7.7% -0.3% 4.6% -3.3% 1.4% 1.4%
R&D 2,496.86
2,664.79
3,219.04
4,248.00
4,006.00
3,840.00
3,562.00
3,737.00
4,116.00
4,207.00
4,819.00
growth rate 6.7% 20.8% 32.0% -5.7% -4.1% -7.2% 4.9% 10.1% 2.2% 14.6%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 2,333.00
2,378.00
2,355.00
2,500.00
2,176.00
growth rate 1.9% -1.0% 6.2% -13.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 4,479.00
4,765.00
5,839.00
5,077.00
5,327.00
growth rate 6.4% 22.5% -13.1% 4.9%
Acct.Payable 1,277.00
1,171.00
1,366.00
1,403.00
1,256.00
growth rate -8.3% 16.7% 2.7% -10.5%
Cur.Assets 19,099.00
24,380.00
19,385.00
18,520.00
19,322.00
growth rate 27.7% -20.5% -4.5% 4.3%
Total Assets 59,773.00
64,993.00
61,165.00
59,196.00
59,294.00
growth rate 8.7% -5.9% -3.2% 0.2%
Cash 6,630.00
11,969.00
7,989.00
6,528.00
5,203.00
growth rate 80.5% -33.3% -18.3% -20.3%
Inventory 4,115.00
4,152.00
4,086.00
4,411.00
4,554.00
growth rate 0.9% -1.6% 8.0% 3.2%
Cur.Liabilities 14,585.00
14,842.00
12,184.00
12,886.00
12,618.00
growth rate 1.8% -17.9% 5.8% -2.1%
Liabilities 51,526.00
56,776.00
54,465.00
58,280.00
56,875.00
growth rate 10.2% -4.1% 7.0% -2.4%
LT Debt 28,458.00
33,291.00
33,222.00
36,010.00
35,705.00
growth rate 17.0% -0.2% 8.4% -0.9%
Equity 8,247.00
8,217.00
6,700.00
916.00
2,419.00
growth rate -0.4% -18.5% -86.3% 164.1%
Common Shares 31,877.00
31,989.00
32,096.00
31,247.00
31,343.00
growth rate 0.4% 0.3% -2.7% 0.3%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 185.00
242.00
287.00
190.00
246.00
growth rate 30.8% 18.6% -33.8% 29.5%
Cash Dividends 1,008.00
999.00
990.00
1,080.00
1,038.00
growth rate -0.9% -0.9% 9.1% -3.9%
Cash From OA 1,931.00
2,418.00
2,808.00
2,164.00
1,930.00
growth rate 25.2% 16.1% -22.9% -10.8%
Sale Purchase of Stock
growth rate
FCF 1,746.00
2,176.00
2,521.00
1,974.00
1,684.00
growth rate 24.6% 15.9% -21.7% -14.7%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 6,526.00
6,706.00
6,846.00
6,238.00
6,594.00
growth rate 2.8% 2.1% -8.9% 5.7%
Op.Income 2,333.00
2,378.00
2,355.00
2,500.00
2,176.00
growth rate 1.9% -1.0% 6.2% -13.0%
IBT 558.00
2,155.00
2,131.00
1,675.00
1,531.00
growth rate 286.2% -1.1% -21.4% -8.6%
Net Income 464.00
1,884.00
1,899.00
1,476.00
1,317.00
growth rate 306.0% 0.8% -22.3% -10.8%
EPS
growth rate
Gross Profit 4,889.00
5,097.00
5,128.00
4,677.00
5,084.00
growth rate 4.3% 0.6% -8.8% 8.7%
R&D 1,082.00
1,422.00
1,348.00
959.00
1,039.00
growth rate 31.4% -5.2% -28.9% 8.3%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (1.81)

YOY Growth Grade:

D (33.53)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 27.05 13.41 15.75
EPS / Growth 10.01

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 1.0% 1.0%
Future PE 2.00 14.93 14.93
Future EPS 11.06 11.06 11.06
Value Price
MOS %
5.47
-95.9%
40.83
-69.6%
40.83
-69.6%
MOS Price 2.73 20.42 20.42
IRT 12.53 12.53 12.53

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.